Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eczema drug trial halted midway – what happened?

NCT ID NCT05999799

Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an injectable drug called GSK1070806 in 161 adults with moderate to severe atopic dermatitis (eczema) who had already tried other treatments. The goal was to see if the drug could reduce eczema severity and itching compared to a placebo. However, the trial was terminated early, so results are limited. The drug is not a cure and would require ongoing use to control symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

161 people

The number who actually took part.

Started

Nov 2023

Finished

Jul 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult participants 18 years to 75 years of age * Participants with: * AtD defined by the AAD Consensus Criteria. * Diagnosis of AtD ≥1 year. * An IGA score ≥3. * AtD involvement of ≥10% body surface area (BSA). * EASI score ≥16 * Baseline pruritus numerical rating scale average score for maximum intensity of at least 3. * Participants may have had exposure to 1 biologic therapy meeting at least 1 of the following conditions: * Participants who stopped treatment due to non-response, partial response, loss of efficacy. * Participants who stopped treatment due to intolerance or AEs. * Participant with a recent history less than or equal to (≤6) months prior to the Screening visit) of inadequate response to a stable regimen of prescription topical medication. * Participants for whom prescription topical medications are not tolerated. * Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical study Exclusion Criteria: * Chronic or acute infection requiring treatment with oral or IV antibiotics, antivirals, anti-protozoal, or antifungals within 4 weeks before the Screening visit or anytime between the Screening and Baseline visits. * Superficial skin infections within 1 week before the Screening visit or active infections (including localized infections), or history of recurrent infections (excluding recurrent fungal infections of the nail bed) * Known, pre-existing or suspected parasitic infection within 6 months before the Screening visit. * Symptomatic herpes zoster within 3 months prior to screening * Uncontrolled hypertension. * Current or chronic history of liver disease or known hepatic or biliary abnormalities. * Known or suspected history of immunosuppression, including history of invasive opportunistic infections despite infection resolution or unusually frequent, recurrent, or prolonged infections, per the Investigator's judgment. * Lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years * Breast cancer within the past 10 years. * History or presence of significant medical illness including but not limited to cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, neurological, or psychiatric disorders which in the opinion of the investigator would interfere with the study procedures and/or assessments. * Previously treated with any oral Janus Kinase inhibitor (JAKi) or other kinase inhibitors, experimental or approved. * Uncontrolled chronic disease that might require bursts of oral corticosteroids, e.g., co-morbid severe uncontrolled asthma. * Presence of Hepatitis B surface antibody (HBsAg) or Hepatitis B core antibody (HBcAb) at screening or within 3 months prior to first dose of study intervention. * Positive hepatitis C antibody test result at screening or within 3 months prior to starting study intervention. * Positive hepatitis C RNA test result at screening or within 3 months prior to first dose of study intervention. * Positive HIV antibody test. * Evidence of active or latent TB as documented by medical history, examination, and TB testing with a positive QuantiFERON test at initial Screening visit. * Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dermatitis, atopic are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema dermatitis Eczema immune system disorder skin disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dermatitis, atopic

Contacts and locations

Locations

  • GSK Investigational Site

    Phoenix, Arizona, 85006, United States

  • GSK Investigational Site

    North Little Rock, Arkansas, 72117, United States

  • GSK Investigational Site

    Canoga Park, California, 91303, United States

  • GSK Investigational Site

    Fountain Valley, California, 92708, United States

  • GSK Investigational Site

    Northridge, California, 91325, United States

  • GSK Investigational Site

    Oceanside, California, 92056, United States

  • GSK Investigational Site

    Santa Monica, California, 90404, United States

  • GSK Investigational Site

    Homestead, Florida, 33033, United States

  • GSK Investigational Site

    Oakland Park, Florida, 33334, United States

  • GSK Investigational Site

    Fayetteville, Georgia, 30214, United States

  • GSK Investigational Site

    Thomasville, Georgia, 31792, United States

  • GSK Investigational Site

    Chicago, Illinois, 60614, United States

  • GSK Investigational Site

    Troy, Michigan, 48084, United States

  • GSK Investigational Site

    New York, New York, 10029, United States

  • GSK Investigational Site

    New York, New York, 10075, United States

  • GSK Investigational Site

    Dublin, Ohio, 43016, United States

  • GSK Investigational Site

    West Lake Hills, Texas, 78746, United States

  • GSK Investigational Site

    Buenos Aires, C1055AAO, Argentina

  • GSK Investigational Site

    Capital Federal, C1181ACH, Argentina

  • GSK Investigational Site

    Ciudad Autonoma de Bueno, C1056ABI, Argentina

  • GSK Investigational Site

    Córdoba, X5000AAW, Argentina

  • GSK Investigational Site

    Mendoza, 5500, Argentina

  • GSK Investigational Site

    Rosario, S2002, Argentina

  • GSK Investigational Site

    Pleven, 5800, Bulgaria

  • GSK Investigational Site

    Sofia, 1510, Bulgaria

  • GSK Investigational Site

    Sofia, Bulgaria

  • GSK Investigational Site

    Kelowna, British Columbia, V1Y 4N7, Canada

  • GSK Investigational Site

    Barrie, Ontario, L4M 7G1, Canada

  • GSK Investigational Site

    London, Ontario, N6H 5L5, Canada

  • GSK Investigational Site

    Markham, Ontario, L3P1X2, Canada

  • GSK Investigational Site

    Québec, Quebec, G1W 4R4, Canada

  • GSK Investigational Site

    Beijing, 100044, China

  • GSK Investigational Site

    Chongqing, 400016, China

  • GSK Investigational Site

    Fuzhou, 350014, China

  • GSK Investigational Site

    Guangzhou, China

  • GSK Investigational Site

    Hangzhou, 310006, China

  • GSK Investigational Site

    Shanghai, 200025, China

  • GSK Investigational Site

    Shanghai, China

  • GSK Investigational Site

    Yinchuan, China

  • GSK Investigational Site

    Yiwu, 322000, China

  • GSK Investigational Site

    Prague, 10034, Czechia

  • GSK Investigational Site

    Prague, 128 08, Czechia

  • GSK Investigational Site

    Prague, Czechia

  • GSK Investigational Site

    La Rochelle, 17019, France

  • GSK Investigational Site

    Paris, 75475, France

  • GSK Investigational Site

    Berlin, 10789, Germany

  • GSK Investigational Site

    Hamburg, 22391, Germany

  • GSK Investigational Site

    Münster, 48149, Germany

  • GSK Investigational Site

    Athens, Greece

  • GSK Investigational Site

    Bari, 70124, Italy

  • GSK Investigational Site

    Bologna, 40138, Italy

  • GSK Investigational Site

    Florence, Italy

  • GSK Investigational Site

    Modena, 41124, Italy

  • GSK Investigational Site

    Roma, 00128, Italy

  • GSK Investigational Site

    Roma, 00168, Italy

  • GSK Investigational Site

    Chiba, 272-0033, Japan

  • GSK Investigational Site

    Fukuoka, 807-8556, Japan

  • GSK Investigational Site

    Fukuoka, 812-8582, Japan

  • GSK Investigational Site

    Gunma, 370-0829, Japan

  • GSK Investigational Site

    Hokkaido, 060-0033, Japan

  • GSK Investigational Site

    Hokkaido, 080-0013, Japan

  • GSK Investigational Site

    Kanagawa, 211-0063, Japan

  • GSK Investigational Site

    Osaka, 583-8588, Japan

  • GSK Investigational Site

    Osaka, 593-8324, Japan

  • GSK Investigational Site

    Saitama, 343-8555, Japan

  • GSK Investigational Site

    Chihuahua City, 31000, Mexico

  • GSK Investigational Site

    Durango, 34000, Mexico

  • GSK Investigational Site

    Guadalajara, 44628, Mexico

  • GSK Investigational Site

    Monterrey, 64718, Mexico

  • GSK Investigational Site

    Panama City, 7099, Panama

  • GSK Investigational Site

    Chojnice, 89-600, Poland

  • GSK Investigational Site

    Elblag, 82-300, Poland

  • GSK Investigational Site

    Katowice, 40-600, Poland

  • GSK Investigational Site

    Poznan, 60-569, Poland

  • GSK Investigational Site

    Szczecin, 70-332, Poland

  • GSK Investigational Site

    Warsaw, 03-291, Poland

  • GSK Investigational Site

    Ansan, 15355, South Korea

  • GSK Investigational Site

    Seoul, 03722, South Korea

  • GSK Investigational Site

    Seoul, 04564, South Korea

  • GSK Investigational Site

    Seoul, 04763, South Korea

  • GSK Investigational Site

    Seoul, 150-950, South Korea

  • GSK Investigational Site

    Alicante, 03010, Spain

  • GSK Investigational Site

    Córdoba, 14004, Spain

  • GSK Investigational Site

    Granada, 18016, Spain

  • GSK Investigational Site

    Madrid, 28222, Spain

  • GSK Investigational Site

    Vigo, 36206, Spain

  • GSK Investigational Site

    Zaragoza, 50009, Spain

  • GSK Investigational Site

    Bangkok, 10330, Thailand

  • GSK Investigational Site

    Pathum Thani, 12120, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.